JPM: Roche Licenses Dyno Therapeutics’ AAV Vector for Neurological Gene Therapy

Press
January 15, 2025
Gen Eng News
TOC LINK
TOC LINK
Press
Published 
January 15, 2025

More like this

Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design

Announcements
Dyno Therapeutics
April 8, 2026

Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design

Announcements
Dyno Therapeutics
April 8, 2026

Dyno Therapeutics Launches Dyno Psi-Phi, an Agentic AI Suite for Protein Binder Design, at NVIDIA GTC 2026

Announcements
Dyno Therapeutics
March 18, 2026

Dyno Therapeutics Launches Dyno Psi-Phi, an Agentic AI Suite for Protein Binder Design, at NVIDIA GTC 2026

Announcements
Dyno Therapeutics
March 18, 2026

Dyno Therapeutics Launches Dyno-yp2, a Top-Performing TfR1-Mediated AAV Capsid, to Further Diversify CNS Delivery Portfolio

Announcements
Dyno Therapeutics
January 12, 2026

Dyno Therapeutics Launches Dyno-yp2, a Top-Performing TfR1-Mediated AAV Capsid, to Further Diversify CNS Delivery Portfolio

Announcements
Dyno Therapeutics
January 12, 2026

Dyno Therapeutics and Trisk Bio Announce Strategic Manufacturing Partnership Through Expanded Frontiers Program

Announcements
Dyno Therapeutics
November 11, 2025

Dyno Therapeutics and Trisk Bio Announce Strategic Manufacturing Partnership Through Expanded Frontiers Program

Announcements
Dyno Therapeutics
November 11, 2025
™ 
343 Arsenal St
Watertown, MA 02472
© Dyno 2025
Privacy PolicyTerms + Conditions